Clinical Trial: PrEPared to Choose (PtC) is an Implementation Study of the Delivery of Cabotegravir Long-acting, an Injectable Pre-exposure Prophylaxis (PrEP) Option for HIV Prevention. Injectable PrEP Will Be Offered Alongside Oral and Vaginal Ring PrEP from Within a Real-world Context in Cape Town, South Africa.

U.S., Feb. 5 -- ClinicalTrials.gov registry received information related to the study (NCT06807736) titled 'PrEPared to Choose (PtC) is an Implementation Study of the Delivery of Cabotegravir Long-acting, an Injectable Pre-exposure Prophylaxis (PrEP) Option for HIV Prevention. Injectable PrEP Will Be Offered Alongside Oral and Vaginal Ring PrEP from Within a Real-world Context in Cape Town, South Africa.' on Jan. 14.

Brief Summary: The goal of this clinical trial is to offer adolescents and young people in Cape Town, South Africa different HIV pre-exposure prophylaxis (PrEP) products and describe how they use these products over an 18-month period. The study has both clinical and implementation primary aims. The primary clinical aim is sho...